Published in Cardiovascular Business Week, April 6th, 2004
The drug-eluting stent will be based upon technology jointly developed by CardioTech and Implant Sciences over the past 3 years, featuring a drug delivery system based upon Chronoflex DES, a proprietary polymeric formulation manufactured exclusively by CardioTech, plus an exclusive thin radiopaque coating manufactured by Implant Sciences.
CardioTech and Implant Sciences have each contributed specialized technology plus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.